Skip to main content

Table 1 Baseline Characteristics

From: The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience

Variables

Total (N = 160)

Gender, n (%)

 Male

52 (32.5)

 Female

108 (67.5)

Age (years), median (min-max)

58 (22–78)

NAFLD, n (%)

 Yes

115 (71.9)

 No

45 (28.1)

SIBO, n (%)

 Yes

55 (34.4)

 No

105 (65.6)

Obesity, n (%)

 Yes

107 (66.9)

 No

53 (33.1)

DM, n (%)

 Yes

120 (75)

 No

40 (25)

Dyslipidemia, n (%)

 Yes

129 (80.6)

 No

31 (19.4)

Metabolic Syndrome, n (%)

 Yes

122 (76.3)

 No

38 (23.8)

Central Obesity, n (%)

 Yes

149 (93.1)

 No

11 (6.9)

Fibrosis Degree, n (%)

 F0-F1

89 (77.4)

 F2-F4

26 (22.6)

Steatosis Degree, n (%)

 S0

41 (26.4)

 S1

10 (6.4)

 S2

4 (2.5)

 S3

60 (38.7)

Significant Steatosis, n (%)

 Yes

71 (61.7)

 No

44 (38.3)

  1. SIBO Small Intestinal Bacterial Overgrowth, NAFLD Non-Alcoholic Fatty Liver Disease, DM Diabetes Mellitus, PR Prevalence Ratio, CI Confidence Interval